IP Library Granted Patent US 7,442,525
Granted Patent B1
US 7,442,525 · App. 08/443,118 · Granted Oct 28, 2008

Method for expressing HIV polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,442,525
App. No.
08/443,118
Granted
Oct 28, 2008
Kind
B1
Abstract

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

Claims (18)

1. In a method for producing an expression product which comprises growing a unicellular microorganism host in a nutrient medium, wherein the unicellular microorganism host comprises a DNA construct having transcriptional and translational initiation and termination regulatory signals functional in the host and a DNA sequence having an open reading frame and under the regulatory control of the signals, whereby said expression product is produced, the improvement comprising:

employing a DNA sequence of at least 27 base pairs of (a) a pol human immunodeficiency virus (HIV) sequence which sequence is within a BstIX (3006) to NdeI (5131) region, said restriction sites as shown in FIG. 4 , (b) a gag HIV sequence as shown in FIG. 4 , or (c) an env HIV sequence as shown in FIG. 4 .

2. A method according to claim 1 wherein said sequence is a gag sequence as shown in FIG. 4 .

3. A method according to claim 1 wherein said sequence is an env sequence as shown in FIG. 4 .

4. A method according to claim 1 wherein said DNA sequence is within BstXI (3006) to Nde I (5131) region, said restriction sites as shown in FIG. 4 .

5. A method according to claim 1 wherein the sequence has at least 50 base pairs.

6. A method according to claim 1 wherein the host is selected from the group consisting of E. coli, B. subtilis, P. aerugenosa, S. cerevisiae and N. crassa.

7. A method according to claim 1 wherein said DNA sequence encodes a complete pol protein, a complete gag protein, or a complete env protein.

8. A method according to claim 1 wherein the expression product is selected from the group consisting of p18 gag or p25.

9. In a method for producing an expression product which comprises growing mammalian host cells comprising a DNA construct comprising transcriptional and translational initiation and termination regulatory signals functional in the host cells and a DNA sequence, said sequence having an open reading frame and an initiation codon at its 5′ terminus and under the transcriptional and translational control of said regulatory signals, whereby a polypeptide encoded by said sequence is expressed; the improvement comprising:

employing a DNA sequence of at least 27 base pairs and less than the whole human immunodeficiency virus (HIV) genome of (a) a pol HIV sequence which sequence is within BstXI (3006) to Nde I (5131) region, said restriction sites as shown in FIG. 4 , (b) a gag HIV sequence as shown in FIG. 4 , or (c) an env HIV sequence as shown in FIG. 4 .

10. A method according to claim 9 wherein said DNA is a gag sequence as shown in FIG. 4 .

11. A method according to claim 9 wherein said DNA is an env sequence as shown in FIG. 4 .

12. A method according to claim 9 wherein said DNA corresponds to a sequence within EcoR 5 (2985) to Mbo II (3447) or within Hpa I (3659) to Nde I (5131) shown in FIG. 4 .

13. A method according to claim 9 wherein said sequence has at least 50 base pairs.

14. A method according to claim 9 wherein said DNA sequence encodes a complete pol protein, a complete gag protein, or a complete env protein.

15. A method according to claim 9 wherein the expression product is selected from the group consisting of p18 gag or p25.

16. A method according to claim 1 wherein said DNA corresponds to a sequence within EcoR 5 (2985) to Mbo II (3447) or within Hpa I (3659) to Nde I (5131) shown in FIG. 4 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE AND ASSIGNOR. PREVIOUSLY RECORDED ON REEL 033886 FRAME 0313. ASSIGNOR(S) HEREBY CONFIRMS THE CONFIRMATORY ASSIGNMENT. Recorded Oct 20, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 034116/0974 →
CONFIRMATORY ASSIGNMENT Recorded Oct 2, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG; GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 033886/0313 →
CHANGE OF NAME Recorded Jul 10, 2008
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 021227/0710 →